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This is the second case study published in a series in the American Journal of Infection 
Control (AJIC) since the Centers for Disease Control and Prevention/ National Healthcare 
Safety Network (NHSN) surveillance definition update of 2015. These cases reflect some of 
the complex patient scenarios IPs have encountered in their daily surveillance of healthcare-
associated infections (HAI) using NHSN definitions. Objectives have been previously 
published. (1)
With each case, a link to an online survey is provided, where you may answer the questions 
posed and receive immediate feedback in the form of answers and explanations. All 
individual participant answers will remain confidential, although it is the authors’ intention 
to share a summary of the findings at a later date. Cases, answers, and explanations have 
been reviewed and approved by NHSN staff. We hope that you will take advantage of this 
offering, and we look forward to your active participation. The online survey may be found 
at: https://www.surveymonkey.com/s/AJIC-NHSN-2015C2
We strongly recommend that you review/reference the NHSN Patient Safety Component 
Manual, Device-Associated Module for information you may need to answer the case study 
questions. The website link is http://www.cdc.gov/nhsn/PDFs/pscManual/
4PSC_CLABScurrent.pdf
The findings and conclusions in this case study are those of the authors and do not 
necessarily represent the official position of the Centers for Disease Control and Prevention.
For each question, please select the most correct answer.
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Scenario 1
Assume your facility is actively enrolled in NHSN and that your monthly reporting plan 
includes central line-associated bloodstream infection (CLABSI) surveillance in all ICUs, 
medical, surgical, and medical-surgical wards.
On January 4th 2015, a 10-year-old female patient has been in your facility’s pediatric 
intensive care unit (PICU) for the last 4 days. She was admitted for remission induction 
chemotherapy for acute myelogenous leukemia and had a peripherally inserted central 
catheter (PICC) inserted on admission. She weighs 25 kg. Today, on her 3rd day of 
chemotherapy, she experiences 625 mg of diarrhea, abdominal pain and vomiting. Her 
absolute neutrophil count (ANC) is 400 cells/mm3.
On January 5th, she passes a total of 500 mg of diarrhea and vomits. Her ANC is 320 
cells/mm3.
On January 6th, her ANC is 300 cells/mm3 and her diarrhea is improved. She has only had 
one episode of vomiting today.
On January 7th, she becomes disoriented and hypotensive. Her ANC level is 180 cells/mm3. 
Blood is collected from her PICC line and from a peripheral venipuncture and a urine 
culture is also collected.
On January 8th, the blood culture, collected from the PICC line the previous day, is positive 
for Escherichia coli while the blood culture collected from the venipuncture site is negative. 
The urine culture result is negative. The patient has been afebrile since admission. 
Antibiotics are started
Antibiotics continue on January 10th and her ANC is 580 cells/mm3. The patient’s ANC and 
white blood cell count (WBC) both remain above 500 cells/mm3 for the remainder of her 
hospital stay.
Question 1. Which of the following statements is most correct?
a. Patient meets criterion 1 for a Laboratory Confirmed Bloodstream Infection 
(LCBI).
b. Patient meets criterion 1 for a Mucosal Barrier Injury-LCBI (MBI-LCBI).
c. Patient meets criterion 2 for an MBI-LCBI.
d. Patient meets criterion 2 for a Gastrointestinal Infection (GIT) and the bloodstream 
infection is secondary to that site of infection.
Explanation
Although on first pass the patient appears to meet criteria for a GIT infection, the symptoms 
used to meet the criteria, i.e., diarrhea, abdominal pain, and vomiting, are all chemotherapy 
side effects. The GIT infection criterion specifically states that these symptoms cannot be 
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due to another, non-infectious cause (2). Therefore they cannot be used to meet the GIT 
criterion.
The patient meets LCBI criterion 1 with a pathogen, not related to an infection at another 
site, recovered from a blood culture. The patient further meets MBI-LCBI criterion 1 since 
E. coli is included as an MBI-LCBI 1 organism and the patient fulfills the NHSN protocol 
requirements for 2 days with ANC levels below 500 cells/mm3 in the 7-day period 
surrounding the blood culture (i.e., 3 days before the day of blood culture collection, the day 
of blood culture collection [January 7th] and the 3 days following blood culture collection). 
See Table 1, Calendar of MBI-LCBI Elements, below.
The date of the LCBI is January 7th, the date that the first element of the infection criterion 
occurred for the first time in the infection window period. Because the date of the LCBI was 
after day-2 of admission, this is a healthcare-associated infection. Since the central line was 
in place greater than 2 days on the date of the LCBI, this is a CLABSI LCBI-1.
The positive blood culture collected from the PICC line must be used to meet the NHSN 
LCBI criterion even though the blood culture collected via the venipuncture site is 
negative.(3)
Scenario 2
Changes from scenario 1 are bolded
On January 4th, a 10-year-old female patient has been in your facility’s PICU for the last 4 
days. She was admitted for remission induction chemotherapy for acute myelogenous 
leukemia and had a peripherally inserted central catheter (PICC) inserted on admission. She 
weighs 25 kg. Today, on her 3rd day of chemotherapy, she experiences 625 mg of diarrhea, 
abdominal pain and vomiting. Her absolute neutrophil count (ANC) is 400 cells/mm3.
On January 5th, she passes a total of 500 mg of diarrhea, and has vomiting. Her ANC is 320 
cells/mm3.
On January 6th, her ANC is 300 cells/mm3 and her diarrhea is improved. She has only had 
one episode of vomiting today.
On January 7th, she becomes disoriented and hypotensive. Her ANC level is 180 cells/mm3. 
Blood is collected from her PICC line as well as from a peripheral venipuncture and a urine 
culture is also collected.
On January 8th, the blood culture, collected from the PICC line the previous day, is positive 
for Escherichia coli while the blood culture collected from the venipuncture site is negative. 
The urine culture result is negative. The patient has been afebrile since admission. 
Antibiotics are started.
Antibiotics continue on January 10th and her ANC is 580 cells/mm3. The patient’s ANC and 
WBC both remain above 500 cells/mm3 for the remainder of her hospital stay.
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On January 16th, the patient becomes listless and has shaking chills. Blood cultures are 
collected, and the next day, Enterococcus faecium is identified in that blood culture.
NOTE: NHSN has developed a surveillance worksheet to promote consistent surveillance 
data collection. That worksheet, along with an example of a completed worksheet with 
explanation, is available under “Supporting Materials” at this site: http://www.cdc.gov/nhsn/
acute-care-hospital/clabsi/index.html Please note that there are 2 tabs at the bottom of each 
of these excel documents, and review information in both tabs. We recommend that you 
access and print these forms to use as you work through this exercise and in your routine 
surveillance activities.
Question 2. Which of the following statements is most correct?
a. This patient has a BSI which is not catheter-associated and which should be 
reported with a date of event of January 16th.
b. This patient has both a CLABSI with E. coli on January 7th and a CLABSI with E. 
faecium on January 16th. Both infections are reported to NHSN.
c. The pathogen E. faecium should be added to the E. coli reported for the 
CLABSI dated January 7th, and not reported as a second CLABSI.
d. Patient meets criterion 2 for a Gastrointestinal Infection (GIT) and both 
bloodstream infections are secondary to that site of infection.
Explanation
Because the E faecium blood culture is collected during the Repeat Infection Window of the 
E.coli CLABSI, and E. faecium is an eligible organism for MBI-LCBI, it is not reported as a 
separate LCBI. Instead, the organism is added as a pathogen to the E. coli reported for 
January 7th.
Scenario 3
Changes from scenario 2 are bolded.
On January 4th, a 10-year-old female patient has been in your facility’s PICU for the last 4 
days. She was admitted for remission induction chemotherapy for acute myelogenous 
leukemia and had a peripherally inserted central catheter (PICC) inserted on admission. She 
weighs 25 kg. Today, on her 3rd day of chemotherapy, she experiences 625 mg of diarrhea, 
abdominal pain and vomiting. Her absolute neutrophil count (ANC) is 400 cells/mm3.
On January 5th, she passes a total of 500 mg of diarrhea, and has vomiting. Her ANC is 320 
cells/mm3.
On January 6th, her ANC is 300 cells/mm3 and her diarrhea is improved. She has only had 
one episode of vomiting today.
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On January 7th, she becomes disoriented and hypotensive. Her ANC level is 180 cells/mm3. 
Blood is collected from her PICC line as well as from a peripheral venipuncture and a urine 
culture is also collected.
On January 8th, the blood culture, collected from the PICC line the previous day, is positive 
for Escherichia coli while the blood culture collected from the venipuncture site is negative. 
The urine culture is also positive for E. coli > 100,000 CFU/ml. The patient has been 
afebrile since admission. Antibiotics are started.
Antibiotics continue on January 10th and her ANC is 580 cells/mm3. The patient’s ANC and 
WBC both remain above 500 cells/mm3 for the remainder of her hospital stay.
On January 16th, the patient becomes listless and has shaking chills. Blood cultures are 
collected, and the next day, E. faecium is identified in that blood culture.
Question 3. Which of the following statements is most correct?
a. Patient meets criteria 1 for a CLABSI with both E. coli and E. faecium.
b. Patient meets criteria for a SUTI 1a with both E. coli and E. faecium.
c. Patient meets criteria for an Asymptomatic Bacteremic Urinary Tract (ABUTI) 
with both E. coli and E. faecium.
d. Patient meets criterion for an ABUTI. The E. coli bloodstream infection is 
secondary to the ABUTI. The patient also meets criteria for a CLABSI with E. 
faecium.
Explanation
The patient, who is not catheterized, is without any of the NHSN symptoms of UTI, i.e. no 
fever, suprapubic tenderness, costovertebral angle pain or tenderness, urinary urgency, 
frequency, nor dysuria. Also at least one bacterium with a colony count of ≥ 100,000 
CFU/ml which is cultured from the urine matches a bacterium in the blood culture. There 
were no more than 2 organisms with a colony count of ≥ 100,000 CFU/ml cultured from the 
urine which was collected on January 7th, making this an acceptable urine culture for NHSN 
UTI surveillance purposes. This patient meets the criteria for an ABUTI as all elements of 
the criterion occurred during the ABUTI infection window period.4
Only primary bloodstream infections are reported to NHSN as LCBI. The NHSN LCBI 
criterion states “Patient has a recognized pathogen cultured from one or more blood cultures 
AND organism cultured from blood is not related to an infection at another site.” In this 
scenario, since the positive blood culture with the matching blood culture (E. coli) is an 
element of the ABUTI criteria, the E. coli BSI is considered secondary to the ABUTI.
During the ABUTI secondary BSI attribution period, a blood culture was collected and was 
positive for E. faecium. Although this blood culture was collected during the secondary BSI 
attribution period, E. faecium does not match the organism identified in the ABUTI, as is 
required to meet ABUTI criteria.4 Therefore, unless there is another site of infection to 
which the E. faecium BSI can be attributed as secondary, this will be a primary BSI and 
Allen-Bridson et al. Page 5
Am J Infect Control. Author manuscript; available in PMC 2016 October 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
CLABSI, meeting LCBI criterion 1, for NHSN reporting purposes. This is not an MBI-
LCBI 1 because there were not at least 2 days of ANC or WBC below 500 cells/mm3 during 
the 3 days before, the day of, or 3 days after the blood culture collection date, nor is she an 
allogeneic hematopoietic stem cell transplant recipient within the past year.
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Table 1
Calendar of MBI-LCBI Elements (applies to Scenario 1)
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